Trials / Unknown
UnknownNCT05106907
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
An Open and Single Dose-escalation Study to Evaluate the Safety and Clinical Activity of Allogeneic CAR-T Targeting CD19(ThisCART19) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma (r/r B-NHL)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Fundamenta Therapeutics, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A single arm, open-label, dose-escalation study to evaluate the safety and clinical activity of ThisCART19 (Allogeneic CAR-T targeting CD19) in patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
Detailed description
ThisCART19 cell is a non-gene-editing allogeneic CAR-T cell targeting CD19. This study is designed to evaluate the safety and clinical activity of ThisCART19 in patients with CD19 positive, relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ThisCART19 cells | 0.2-60 x 10\^6 CAR T cells per kg body weight |
Timeline
- Start date
- 2021-10-25
- Primary completion
- 2023-10-24
- Completion
- 2024-10-24
- First posted
- 2021-11-04
- Last updated
- 2021-11-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05106907. Inclusion in this directory is not an endorsement.